Amyotrophic lateral sclerosis progression is tracked in plasma by systemic proteins independent of motor neurons

Blood biomarkers that change as patients with amyotrophic lateral sclerosis (ALS) decline would allow progression to be monitored more objectively. Plasma proteomic studies have identified proteins that differ between patients and controls, but which plasma proteins change as patients decline, and whether they come from motor neurons, is unknown. Here, we leveraged the Answer ALS cohort, with serial SomaScan plasma proteomics, repeated ALS Functional Rating Scale-Revised assessments, and induced pluripotent stem cell-derived motor neurons (iMNs) from the same patients. At baseline, 77 plasma proteins differed between 245 patients and 76 controls. These were dominated by muscle proteins, including PDLIM3, ACTN2, and MYOM2, and reflected disease severity. Using a two-stage longitudinal design, we identified 72 progression markers whose within-patient change tracked the rate of functional decline, led by CLEC3B, ANTXR2, and ART3. These were largely distinct from the most elevated muscle proteins and were secreted or shed proteins spread across many tissues. Both sets replicated in the independent Target ALS cohort. A motor neuron expression map built from the iMNs showed that motor neuron proteins were underrepresented in both sets and that expression in iMNs did not predict tracking of decline. Baseline serum neurofilament light chain (NfL) predicted how quickly patients declined but its change did not track decline, whereas change in the progression markers did so within every stratum of baseline NfL. Neither tracked decline in the fastest progressing patients. This positions baseline NfL for prognosis and stratification and systemic plasma proteins for monitoring.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-20
DOI
https://doi.org/10.64898/2026.11.15.26368153
Primary Topic
Amyotrophic Lateral Sclerosis Research
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Amyotrophic lateral sclerosis progression is tracked in plasma by systemic proteins independent of motor neurons

Caitlin A. Finney, Artur Shvetcov
5 links
medRxiv
Amyotrophic Lateral Sclerosis Research
preprint

Amyotrophic lateral sclerosis progression is tracked in plasma by systemic proteins independent of motor neurons

Caitlin A. Finney, Artur Shvetcov
preprint en

Abstract

Blood biomarkers that change as patients with amyotrophic lateral sclerosis (ALS) decline would allow progression to be monitored more objectively. Plasma proteomic studies have identified proteins that differ between patients and controls, but which plasma proteins change as patients decline, and whether they come from motor neurons, is unknown. Here, we leveraged the Answer ALS cohort, with serial SomaScan plasma proteomics, repeated ALS Functional Rating Scale-Revised assessments, and induced pluripotent stem cell-derived motor neurons (iMNs) from the same patients. At baseline, 77 plasma proteins differed between 245 patients and 76 controls. These were dominated by muscle proteins, including PDLIM3, ACTN2, and MYOM2, and reflected disease severity. Using a two-stage longitudinal design, we identified 72 progression markers whose within-patient change tracked the rate of functional decline, led by CLEC3B, ANTXR2, and ART3. These were largely distinct from the most elevated muscle proteins and were secreted or shed proteins spread across many tissues. Both sets replicated in the independent Target ALS cohort. A motor neuron expression map built from the iMNs showed that motor neuron proteins were underrepresented in both sets and that expression in iMNs did not predict tracking of decline. Baseline serum neurofilament light chain (NfL) predicted how quickly patients declined but its change did not track decline, whereas change in the progression markers did so within every stratum of baseline NfL. Neither tracked decline in the fastest progressing patients. This positions baseline NfL for prognosis and stratification and systemic plasma proteins for monitoring.

medRxiv
Westmead Institute for Medical Research (AU)
Neil and Norma Hill Foundation, National Health and Medical Research Council, Medical Research Future Fund
Good health and well-being
Amyotrophic Lateral Sclerosis Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Amyotrophic lateral sclerosis progression is tracked in plasma by systemic proteins independent of motor neurons — Caitlin A. Finney, Artur Shvetcov · medRxiv (2026) | TGRS Research Map | TGRS